WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Infosys and Top Pharma Bring Digital Transformation to DrugManufacturing Data
April 1, 2022
I'm For Real
Enter your details once to access all our information and resources
The Pharmaceutical Development Institute (PDI) is a knowledge resource for pharmaceutical and biotech drug development companies providing training and professional development programs.
whitePaper | May 18, 2022
Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.
whitePaper | December 28, 2022
Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical.
whitePaper | October 25, 2022
To confirm the suitability of empty hard capsules for use in the application of quality-by-design (QbD) in the development and manufacturing of finished pharmaceutical products, the quality target product profile (QTPP) defined by eight critical quality attributes (CQA’s) was examined.
whitePaper | January 1, 2020
Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.
whitePaper | February 15, 2023
Pediatric populations represent the most diverse patient groups in all of medicine. Factors such as individual preferences, physiology, and dosage considerations all serve to complicate drug formulation aimed at pediatric care.
whitePaper | June 22, 2022
The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE